A cross-practice team of Ropes & Gray attorneys advised Cambrex Corporation in its agreement to acquire Avista Pharma Solutions for approximately $252 million. The deal was announced on Nov. 20.
Cambrex is a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, and Avista Pharma Solutions is a contract development, manufacturing and testing organization. Avista is a portfolio company of Ampersand Capital Partners, a health care focused private equity firm. The acquisition of Avista strengthens Cambrex’s position as a leading fully integrated small molecule contract development and manufacturing organization across the entire drug lifecycle.
The Ropes & Gray team includes securities & public companies associate Thomas Fraser, tax & benefits partner David Saltzman (both of Boston) real estate partner Peter Alpert, securities & public companies partner Paul Kinsella (all of Boston), life sciences partner Albert Cacozza (Washington, D.C.).
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.